Table 1 Characteristics of the studies included in the meta-analysis
Study | Design | Location | Study period | Treatment groups | No. of patients | Median dose (g/d) | Median duration (d) | ICU admission % | Definition of mortality |
|---|---|---|---|---|---|---|---|---|---|
Lee 2011 [13] | SC retrospective PS-matched case- control study | South Korea | 2004–2009 | CFZ | 49 | NR | 17 | NR | 30-day over mortality |
NAF | 84 | NR | 15 | NR | 90-day SAB-related mortality | ||||
Paul 2011 [14] | SC retrospective cohort study | Israel | 1988–1994 & 1999–2007 | CFZ | 72 | NR | NR | 5.2 | 30-day all-cause mortality |
CLX | 281 | NR | NR | 90-day mortality | |||||
Renaud 2011 [15] | SC retrospective cohort study | Singapore | 2009 | CFZ | 14 | 2 | NR | NR | 30-day mortality |
CLX | 13 | 2–8 | NR | NR | |||||
Li 2014 [16] | MC retrospective cohort study | USA | 2008–2012 | CFZ | 59 | 6 | 31 | 7 | 30-day all-cause mortality |
OXA | 34 | 12 | 39 | 18 | 90-day all-cause mortality | ||||
Bai 2015 [17] | MC retrospective PS-matched cohort study | Canada | 2007–2010 | CFZ | 105 | 3 | NR | 10 | 90-day mortality |
CLX | 249 | 12 | NR | 18 | |||||
Rao 2015 [18] | MC retrospective cohort study | USA | 2010–2013 | CFZ | 103 | 6 | 29 | 41.8 | All-cause in-hospital mortality |
OXA | 58 | 12 | 32.5 | 32.8 | |||||
Pollett 2016 [19] | SC prospective PS-matched cohort study | USA | 2008–2013 | CFZ | 70 | NR | 20 | 13 | 90-day all-cause mortality |
NAF | 30 | NR | 12 | 27 | |||||
Flynt 2017 [20] | MC retrospective cohort study | USA | 2013–2015 | CFZ | 68 | 6 | NR | NR | 30-day all-cause mortality |
NAF | 81 | 12 | NR | NR | |||||
McDanel 2017 [21] | MC retrospective cohort study | USA | 2003–2010 | CFZ | 1163 | NR | NR | 15 | 30-day all-cause mortality |
NAF/ OXA | 2004 | NR | NR | 19 | 90-day all-cause mortality | ||||
Lee 2018 [22] | MC prospective PS-matched cohort study | South Korea | 2013–2015 | CFZ | 79 | NR | NR | NR | 90-day all-cause mortality |
NAF | 163 | NR | NR | NR | 30-day all-cause mortality |